Abstract Library

#4520 Is late diagnosis and carcinoid heart disease (CaHD) associated with deprivation index? – An audit of practice and assessment of deprivation index in Sheffield ENETS Centre of Excellence

Introduction: Delays to diagnosis in neuroendocrine neoplasms is a world-wide problem. Challenges and inequities recognised include low awareness and access to expert centres. Indices of multiple deprivation (IMD) assess the least to the most deprived areas in the UK, 1 being the most deprived of the 10 deciles.

Conference:

Presenting Author: Munir A

Authors: Abdella O, Abdelhaleem E, Kwok W, Harber J, Rowett O,

Keywords: Index of multiple deprivation, carcinoid syndrome, carcinoid heart disease,

#3432 Fibroblast Activation Protein (FAP)-directed molecular imaging segregates between subtypes of poorly differentiated neuroendocrine neoplasms

Introduction: Fibroblast activation protein (FAP) is overexpressed in highly aggressive gastroenteropancreatic neuroendocrine neoplasms (NEN).

Conference:

Presenting Author: Weich A

Authors: Weich A, Wild V, Higuchi T, Meining A, Rowe S,

Keywords: [68Ga]FAPI, fibroblast activation protein, neuroendocrine, molecular imaging, ert,

#3383 Well-differentiated grade 3 neuroendocrine tumors: Characteristics, treatments and outcomes from a population-based study

Introduction: Well-differentiated grade 3 neuroendocrine tumors (G3 NETs) are a new clinically distinct grouping, however their characteristics, prognosis and treatment outcomes remain unclear.

Conference:

Presenting Author: Boutin M

Authors: Boutin M, Mathews A, Badesha J, Paul A, Safro M,

Keywords: neuroendocrine, grade 3, well-differentiated, treatment, outcome,

#3224 MicroRNAs - 193 and -223 alter NET differentiation markers and shape inflammatory response in vitro

Introduction: Future improvements in NETs therapy depend on treatments tailored to tumor cell characteristics, microenvironment and inflammatory status. We recently reported selective downregulation of microRNAs (miRs) -29 and -223 in serum of NET patients, suggesting a possible role in NET disease.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Geisler L, Özdirik B, Mohr R, Knorr J, Tacke F,

Keywords: miR, NET, BON, in vitro, biomarker, inflammation,

#3159 Wearables in metastatic gastroenteropancreatic neuroendocrine tumors (NETFIT)

Introduction: Patients diagnosed of an advanced neuroendocrine tumor (NET) are frequently deteriorating their quality of life due to tumor volume and growth, hormone-release related symptoms and treatment toxicity. Changes on lifestyle (exercise, nutrition and quality of sleep) of patients with solid tumors have been shown to improve treatment compliance, tolerability, as well as in quality of life. However, patients with NETs have not been included in those studies.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Molina Cerrillo J, Alonso-Gordoa T, Grande E, Benavent M, Garcia-Carbonero R,

Keywords: neuroendocrine tumor, nutritional and exercise assessment, quality of life, trial in progress,